Kato DRC Safety and Treatment Benefit of RESOLV ER¿ in Subjects with Mild to Moderate Non-Proliferative Diabetic Retinopathy
Research Grant
Administered By
Ophthalmology
Awarded By
Kato Pharmaceuticals, Inc
Start Date
October 15, 2019
End Date
December 31, 2021
Administered By
Ophthalmology
Awarded By
Kato Pharmaceuticals, Inc
Start Date
October 15, 2019
End Date
December 31, 2021